reported significant (~ 80%) absorption of bisphenol A (BPA) from solutions applied to the oral cavity of dogs, leading to higher serum BPA (aglycone) concentrations than occurred when BPA was absorbed through the gastro intestinal tract. This finding is consistent with first prin ciples and experience with orally absorbed drugs. The implications for human exposure and health will be clear when experi mental evidence is available regarding the extent and frequency of sublingual absorption in orally exposed humans.
Arguments made by Gayrard et al. that "nanogramspermilliliter" serum concen trations of BPA resulting from sublingual absorption are plausible in humans ignore key pharmaco kinetic and exposure data and con flate issues of serum BPA concentrations with serum BPA/BPAG (BPA glucuronide) ratios.
For a given dose, bolus dosing yields peak concentrations of a parent compound that are higher than those with non bolus dosing. Peak concentrations in mixed systemic serum following sublingual exposure cannot exceed those following intra veneous (iv) dosing. Therefore, in humans, peak systemic serum concentrations following sublingual expo sure cannot be higher than those resulting from bolus iv administration of a given BPA dose. Scaling by dose from pharmaco kinetic studies of non human primates (Patterson et al. 2013) , the human serum concentra tion of aglycone BPA immediately after an iv bolus adminis tra tion of a dose equiva lent to a 95th percentile of aggregate daily U.S. human exposure (0.22 μg/kg body weight; Lakind and Naiman 2010) would be < 0.1 ng/mL, which is below current quanti fication limits (LOQ) using stateoftheart technology. Therefore, peak systemic serum concentrations of aglycone BPA following sublingual exposure/absorption of this dose would also be < LOQ. This result is consis tent with the data of Gayrard et al. (2013) in which dog serum BPA concentrations would be ~ 0.07 ng/mL (i.e., < LOQ) when sampled from a site reflecting systemic expo sure (e.g., leg vein). Therefore, in 95% of the U.S. popu lation, serum aglycone BPA con centrations of nanograms per milliliter are not possible, even with complete sublingual absorption.
Several studies in the literature have reported BPA/BPAG ratios in human serum samples higher than those (< 1%) consis tently observed in human and animal oral pharmaco kinetic studies (Vandenberg et al. 2007 ). Gayrard et al. (2013) introduced a new hypothesis (i.e., sublingual exposure/ absorption) to justify this discrepancy. Previously proffered hypotheses for high BPA and BPA/BPAG ratios in human serum samples included exposures 10,000 times higher (Vandenberg et al. 2007 ) than those measured in humans (Lakind and Naiman 2010) , extensive dermal exposure/absorption (Vandenberg et al. 2013) , and sample contami nation (Teeguarden et al. 2011) . Only the latter hypothesis is supported by ample evidence that contamination of blood samples is not only common, but difficult to avoid (Ye et al. 2013) .
Finally, extrapolation of BPA levels from BPAG levels using the measured ratio of < 1% following ingestion of BPA is appro priate under conditions where BPA reaches the systemic blood via gastro intestinal tract absorption [e.g., food (see Teeguarden et al. 2011)] . Similarly, values of approxi mately 10-20% would be valid for serum levels 0-4 hr after iv dosing or complete sub lingual absorption, when sampled from a site representing systemic exposure. The comments by Teeguarden et al. offer us the opportunity to explain some possible pharmaco kinetic (PK) and PK/ pharmacodynamic (PK/PD) consequences of sub lingual bisphenol A (BPA) absorption. Nowhere in our paper (Gayrard et al. 2013 ) did we report that "nanogramspermilliliter serum concentrations of BPA resulting from sub lingual absorption are plausible in humans." Using elementary PK computation, Teeguarden et al. concluded that peak concentrations in mixed systemic serum should be < 0.1 ng/mL even after a bolus intra veneous (iv) administration based on the 95th percentile of the aggregate daily U.S. human exposure (0.22 μg/ kg body weight). Using the same scaling approach but considering a sub population of chil dren 6-11 years of age with a 95th per centile of 0.481 μg/ kg/ day (Lakind and Naiman 2011) , and taking into account our own data from dogs, the maxi mum initial plasma BPA concen tra tion would be about 0.6 ng/mL. More important, what should be highlighted from our study is that, within 1 hr after administration of the low BPA dose (0.05 mg/kg), the BPA concen tra tions in blood collected from the jugular vein (i.e., downstream from the BPA absorp tion site) were higher than those measured after the corresponding iv adminis tration (see Figure 1B of Gayrard et al. 2013) . Teeguarden et al. should not be confused by the question of validity of a sampling site for making a sound pharmaco kinetic computa tion and the biological relevance of a local concentration that is a biological fact that needs to be considered. Scaling our local jugu lar concentrations by human BPA expo sure (0.22 μg/kg) leads to the computation of a jugular BPA concentration > 1 ng/ mL. What is true for sub lingual absorption and the jugular vein could be true for any sam pling site located down stream of any other Correspondence absorption site, such as the human cubi tal vein after percutaneous absorption of BPA from thermal receipt paper, leading to serum BPA concentrations > 1 ng/mL (vom Saal FS, personal communication) . This means that high BPA concentrations that are neither contamination (vom Saal 2013) nor a violation of PK principles can be observed in humans.
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More generally, it is our opinion that it is unwise to consider that "mixed systemic serum following sublingual exposure" and blood samples obtained "from a site reflecting systemic exposure" are the only valuable ways to describe the PK of BPA and to discuss the PK/PD relationship. The buccal absorp tion of BPA can be viewed as a direct infusion of BPA into the internal jugular vein (in humans) likely to lead down stream to a totally different pattern of BPA biophase exposure compared with intestinal absorption. Buccal absorption should generate a series of BPA peaks (associated with mea ls) and troughs (during the inter digestive period) in the blood rather than a low steady exposure following intestinal absorption. In addition, the amplitude of these inter mittent jumps in BPA concen tration could be higher in arterial blood that those meas ured peripherally. Chiou (1989) reported that after iv adminis tration, measured peripheral venous concen tra tions could be initially lower or much lower than the corre sponding arterial concen trations, which are the driving concentrations to consider for drug action. Chiou also showed that the shorter the terminal halflife, the greater the arterio venous concentration difference during the distribution/redistribution phase. BPA's half life is short, and it makes sense to postulate that the peripheral venous blood BPA concen tra tion meas ured following buccal absorption could systematically under estimate the arterial BPA concentration.
Finally, our article points to new alterna tive hypotheses for interpretation of the current epidemiological urinary data and also for better understanding blood BPA concentrations. First, the bio availability of BPA is now theo reti cally up to 100% rather than about 1%, as expected following oral gavage. Second, given the typical feeding behavior of humans, the lack of uniformity of blood BPA concentrations after buccal absorp tion should not be ignored in terms of the PK/ PD relationship. We are now exploring the hypothesis that sublingual absorp tion can lead to a possible firstpass disrupting effect on pituitary secretions.
